NEW YORK (GenomeWeb News) – Following Thermo Fisher Scientific's announcement today that it is buying One Lambda for $925 million, ratings agency Moody's Investors Service downgraded the company's senior unsecured rating and all rated senior unsecured notes.

Thermo Fisher's unsecured senior rating and notes were downgraded one notch to Baa1 from A3. Moody's affirmed the Prime-2 rating on Thermo Fisher's commercial paper program and said that the rating outlook is stable.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that researchers in Italy are testing a gene drive aimed at controlling mosquito populations.

Researchers may experience the effects of the government shutdown for a while, the Los Angeles Times reports.

A new study finds that the majority of patients at a Tijuana clinic received a diagnosis after first-line genome sequencing, the San Diego Union-Tribune reports.

In Genome Biology this week: post-transcriptional modification-based stratification of glioblastoma, single-cell analysis of gene expression and methylation in human iPSCs, and more.